Can Haematopoietic Progenitor Cell (HPC) Enumeration with the sysmex xe-2100 guide further Flow Cytometric CD34+ Measurements and Timing of Leukapheresis?

Stem cell transplantation is the only curative treatment for a number of haematological and oncological diseases including lymphomas, leukaemias and several solid tumours. Recently the indications for this kind of treatment have been extended into other fields of internal medicine, e.g. autoimmune diseases. For stem cell transplantation it is necessary to have a graft consisting either of autologous or allogeneic cells. The principal sources include bone marrow cells, peripheral blood stem cells or cord blood cells. During the past 30 years the number of bone marrow (BMT) and peripheral blood stem cell transplantations (PBSCT) has increased enormously as shown in figure 1 using data from the International Bone Marrow Transplantation Registry (IBMTR). From IBMTR data it can also be seen that for allogeneic transplants, the source of stem cells increasingly is the peripheral blood for both children and adults (figure 2) and the same holds true for autologous transplants (figure 3) where in adult practice the figure approaches 90%.